SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 14, 2003; DOI 10.1182/blood-2003-06-1856. This Article Full Text (PDF) All Versions of this Article: 2003-06-1856v1 102/12/3912    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Deeg, H J. Articles by Appelbaum, F. R Search for Related Content PubMed PubMed Citation Articles by Deeg, H J. Articles by Appelbaum, F. R Social Bookmarking                   What's this? Submitted June 10, 2003 Accepted August 5, 2003 Allogeneic hemopoietic stem cell transplantation for myelofibrosis H Joachim Deeg*, Theodore A Gooley, Mary E D Flowers, George E Sale, John T Slattery, Claudio Anasetti, Thomas R Chauncey, Kristine Doney, George E Georges, Hans-Peter Kiem, Paul J Martin, Effie W Petersdorf, Jerald Radich, Jean E Sanders, Brenda M Sandmaier, E Houston Warren, Robert P Witherspoon, Rainer Storb, and Frederick R Appelbaum Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA Seattle VA Medical Center, Seattle, WA, USA * Corresponding author; email: jdeeg{at}fhcrc.org. Fifty-six patients, 10-66 years of age, with idopathic myelofibrosis (IMF) or endstage polycythemia vera or essential thrombocythemia received allogeneic hemopoietic cell transplants from related (n=36) or unrelated (n=20) donors. Forty-four patients were prepared with busulfan plus cyclophosphamide, and 12 with total body irradiation plus chemotherapy. The source of stem cells was marrow in 33, and peripheral blood in 23 patients. All but three patients achieved engraftment. While 50 patients showed complete donor chimerism, three patients were found to be mixed chimeras 26, 48, and 86 months post-transplant, respectively. Two patients died from relapse/progressive disease, and 18 from other causes. Thirty-six patients are surviving at 0.5-11.6 (median 2.8) years for a 3-year Kaplan-Meier estimate of 58% (CI 43%, 73%). Dupriez score, cytogenetic abnormalities and degree of marrow fibrosis were the most significant risk factors for post-transplant mortality. Patients conditioned with a regimen of busulfan targeted to plasma levels of 800-900 ng/mL plus cyclophosphamide had a higher probability of survival (76% [CI 62%, 91%]) than other patients. Results with unrelated donors were comparable to those with HLA-identical sibling transplants. Thus, allogeneic hemopoietic cell transplantation offers long-term relapse-free survival for patients with myelofibrosis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Quintas-Cardama, H. M. Kantarjian, T. Manshouri, D. Thomas, J. Cortes, F. Ravandi, G. Garcia-Manero, A. Ferrajoli, C. Bueso-Ramos, and S. Verstovsek Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis J. Clin. Oncol., October 1, 2009; 27(28): 4760 - 4766. [Abstract] [Full Text] [PDF] R. A. Mesa How I treat symptomatic splenomegaly in patients with myelofibrosis Blood, May 28, 2009; 113(22): 5394 - 5400. [Abstract] [Full Text] [PDF] D. Rondelli Allogeneic hematopoietic stem cell transplantation for myelofibrosis Haematologica, October 1, 2008; 93(10): 1449 - 1450. [Full Text] [PDF] S. Chunduri, S. Gaitonde, S. O. Ciurea, R. Hoffman, and D. Rondelli Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation Haematologica, October 1, 2008; 93(10): 1593 - 1595. [Full Text] [PDF] F. Patriarca, A. Bacigalupo, A. Sperotto, M. Isola, F. Soldano, B. Bruno, M. T. van Lint, A. P. Iori, S. Santarone, F. Porretto, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Haematologica, October 1, 2008; 93(10): 1514 - 1522. [Abstract] [Full Text] [PDF] F. Passamonti, E. Rumi, M. Caramella, C. Elena, L. Arcaini, E. Boveri, C. Del Curto, D. Pietra, L. Vanelli, P. Bernasconi, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis Blood, April 1, 2008; 111(7): 3383 - 3387. [Abstract] [Full Text] [PDF] A. Tefferi Primary myelofibrosis and its paraneoplastic stromal effects Haematologica, May 1, 2007; 92(5): 577 - 579. [Full Text] [PDF] N. Kroger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhauser, A. Reiter, T. Zabelina, A. R. Zander, and B. Fehse Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis Blood, February 1, 2007; 109(3): 1316 - 1321. [Abstract] [Full Text] [PDF] R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF] R. A. Mesa Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 355 - 362. [Abstract] [Full Text] [PDF] D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF] C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek Advances in the Therapy of Chronic Idiopathic Myelofibrosis Oncologist, September 1, 2006; 11(8): 929 - 943. [Abstract] [Full Text] [PDF] A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) Blood, September 1, 2006; 108(5): 1497 - 1503. [Abstract] [Full Text] [PDF] A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood, August 15, 2006; 108(4): 1158 - 1164. [Abstract] [Full Text] [PDF] R. L. Levine and G. Wernig Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders Hematology, January 1, 2006; 2006(1): 233 - 239. [Abstract] [Full Text] [PDF] A. Tefferi Pathogenesis of Myelofibrosis With Myeloid Metaplasia J. Clin. Oncol., November 20, 2005; 23(33): 8520 - 8530. [Abstract] [Full Text] [PDF] A. Tefferi and T. Barbui bcr/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and Treatment Mayo Clin. Proc., September 1, 2005; 80(9): 1220 - 1232. [Abstract] [PDF] M. Xu, E. Bruno, J. Chao, S. Huang, G. Finazzi, S. M. Fruchtman, U. Popat, J. T. Prchal, G. Barosi, R. Hoffman, et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases Blood, June 1, 2005; 105(11): 4508 - 4515. [Abstract] [Full Text] [PDF] D. Rondelli, G. Barosi, A. Bacigalupo, J. T. Prchal, U. Popat, E. P. Alessandrino, J. L. Spivak, B. D. Smith, H. G. Klingemann, S. Fruchtman, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia Blood, May 15, 2005; 105(10): 4115 - 4119. [Abstract] [Full Text] [PDF] A. M. Vannucchi, L. Bianchi, F. Paoletti, A. Pancrazzi, E. Torre, M. Nishikawa, M. Zingariello, A. Di Baldassarre, R. A. Rana, R. Lorenzini, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-{beta}1 in the development of myelofibrosis Blood, May 1, 2005; 105(9): 3493 - 3501. [Abstract] [Full Text] [PDF] R. A. Mesa, C.-Y. Li, R. P. Ketterling, G. S. Schroeder, R. A. Knudson, and A. Tefferi Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases Blood, February 1, 2005; 105(3): 973 - 977. [Abstract] [Full Text] [PDF] H. Baurmann, I. Burlakowa, J. Kaltenhaeuser, D. Judith, M. Heshmat, F. Collenbusch, R. Conradi, M. Schleuning, and R. Schwerdtfeger Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis with Myeloid Metaplasia (MMM) - Transplantation Should Be Performed before Transfusion Dependence Occurs. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1513 - 1513. [Abstract] A. Tefferi and H. J. Deeg Deciding on Transplantation for Myelofibrosis: Setting the Record Straight Mayo Clin. Proc., July 1, 2004; 79(7): 953 - 954. [PDF] A. Tefferi The Message Is Not the Median!-Reply-I Mayo Clin. Proc., February 1, 2004; 79(2): 275 - 276. [PDF] S. O'Brien, A. Tefferi, and P. Valent Chronic Myelogenous Leukemia and Myeloproliferative Disease Hematology, January 1, 2004; 2004(1): 146 - 162. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020